M. Scot Roberts - Jul 1, 2022 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role: Chief Scientific Officer
Signature: /s/ Richard Eisenstadt, as Attorney-in-Fact
Stock symbol: ALT
Transactions as of: Jul 1, 2022
Transactions value $: -$365,456
Form type: 4
Date filed: 7/5/2022, 05:15 PM
Previous filing: Jun 30, 2022
Next filing: Aug 3, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALT	Common Stock, par value $0.0001	Options Exercise	$10.4K	+4.02K	+22.71%	$2.60	21.7K	Jul 1, 2022	Direct
transaction	ALT	Common Stock, par value $0.0001	Options Exercise	$67.7K	+23K	+105.73%	$2.95	44.7K	Jul 1, 2022	Direct
transaction	ALT	Common Stock, par value $0.0001	Sale	-$324K	-27K	-60.39%	$12.00	17.7K	Jul 1, 2022	Direct	F1
transaction	ALT	Common Stock, par value $0.0001	Options Exercise	$2.32K	+787	+4.45%	$2.95	18.5K	Jul 5, 2022	Direct
transaction	ALT	Common Stock, par value $0.0001	Sale	-$122K	-10.2K	-55.08%	$12.00	8.31K	Jul 5, 2022	Direct	F1
holding	ALT	Common Stock, par value $0.0001						15	Jul 1, 2022	Shares held by spouse of Reporting Person

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALT	Stock Options (option to buy)	Options Exercise	$0	-4.02K	-31.47%	$0.00	8.75K	Jul 1, 2022	Common Stock, par value $0.0001	4.02K	$2.60	Direct	F2
transaction	ALT	Stock Options (option to buy)	Options Exercise	$0	-23K	-60.43%	$0.00	15K	Jul 1, 2022	Common Stock, par value $0.0001	23K	$2.95	Direct	F2
transaction	ALT	Stock Options (option to buy)	Options Exercise	$0	-787	-5.23%	$0.00	14.3K	Jul 5, 2022	Common Stock, par value $0.0001	787	$2.95	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2	Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date.

Content

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date.